Fundraising Fox
medcura
Riverdale, US · Delaware corporation · 5 known investors
Find your way into medcura
Sign up to see every warm intro you have to medcura
- Paths you didn't know you had: your email and LinkedIn already hold routes to the medcura team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.
Founders & leadership
MD
Matthew Dowling, Ph.DDr. Dowling is the Chief Scientic Officer of the Issuer.
RV
Rich VincentMr. Vincent is the Chief Financial Officer of the Issuer.
LT
PT
Peter ThomasExecutive
MD
Matthew DowlingNamed on SEC filing
Board
AA
Abbas Ardehali, M.D.Board director
Investors · 5
Aspira Capitallisted by Aspira CapitalFort Lee
How we know: Aspira Capital's portfolio page · Not right? Tell us
Delaware Crossing Investor Grouplisted by Delaware Crossing Investor GroupPhiladelphia
How we know: Delaware Crossing Investor Group's portfolio page · Not right? Tell us
Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$60.2M disclosed across 7 rounds · 2016–2025
▶$28.5MraisedJul 2025 · 174 investors · BiotechnologyRule 506(b)
▶$28.5MraisedJul 2025 · 174 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rich VincentExecutive Officer
- Jim BuckDirector, Executive Officer
- Larry TiffanyDirector, Executive Officer
- Abbas Ardehali, M.D.Director
- Matthew Dowling, Ph.DDirector, Executive Officer
- Offering amount
- $38.3M
- Amount sold
- $28.5M
- Finders' fees
- $52.2K
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedJul 2024 · 151 investors · BiotechnologyRule 506(b)
▶$22.5MraisedJul 2024 · 151 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abbas Ardehali, M.D.Director
- Matthew Dowling, Ph.DDirector, Executive Officer
- Jim BuckDirector, Executive Officer
- Rich VincentExecutive Officer
- Larry TiffanyDirector, Executive Officer
- Offering amount
- $22.8M
- Amount sold
- $22.5M
- Sales commissions
- $119K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedNov 2021 · 45 investors · BiotechnologyRule 506(b)
▶$3.5MraisedNov 2021 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim BuckDirector
- Rich VincentExecutive Officer
- Matthew DowlingExecutive Officer, Director
- Larry TiffanyExecutive Officer, Director
- Offering amount
- $5.8M
- Amount sold
- $3.5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedSep 2020 · 55 investors · BiotechnologyRule 506(b)
▶$3MraisedSep 2020 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew DowlingExecutive Officer, Director
- Alex ArrowDirector
- Larry TiffanyExecutive Officer, Director
- Jim BuckDirector
- Rich VincentExecutive Officer
- Offering amount
- $5M
- Amount sold
- $3M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2018 · 36 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJul 2018 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew DowlingExecutive Officer, Director
- Alex ArrowDirector
- Jim BuckDirector
- Larry TiffanyExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedNov 2016 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedNov 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Larry TiffanyDirector
- Alex ArrowDirector
- Matthew DowlingExecutive Officer, Director
- Offering amount
- $3.1M
- Amount sold
- $1.1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11raisedApr 2016 · 1 investors · BiotechnologyRule 506(b)
▶$11raisedApr 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Larry TiffanyDirector
- Peter ThomasExecutive Officer, Director
- Matthew DowlingExecutive Officer, Director
- Offering amount
- $200
- Amount sold
- $11
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
WalgreensWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
ChewyChewy is an online retailer for pet products and prescription medications, offering an Autoship subscription service and a pharmacy where licensed pharmacists coordinate with veterinarians to fill pet prescriptions. It serves pet owners with home delivery of pet supplies and medications.
PractoPracto operates an online healthcare platform offering a directory of verified doctors, appointment booking at hospitals and clinics, online consultations across 20+ specialities, subscription health plans, diagnostic test collection, and medicine delivery. It also provides practice management and hospital information management software for clinics and hospitals.
Companies working in the same space as medcura.
Frequently asked questions
- What does medcura do?
- Medcura develops hemostatic products made from hydrophobically modified biopolymers to control minimal, mild, and moderate surgical bleeding through mechanical mucoadhesion. Its offerings target surgeons, patients, and payers in the surgical hemostasis market, including specialized applications such as spine surgery.
- Who are medcura's investors?
- medcura's investors include Aspira Capital, Delaware Crossing Investor Group, Maryland TEDCO, Robin Hood Ventures, TEDCO.
- How much funding has medcura raised?
- medcura has disclosed $60.2M raised across 7 rounds.
- Where is medcura headquartered?
- medcura is headquartered in Riverdale, US.